Business
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
Webinar to be hosted on Tuesday, March 21, 2023 at 12:00 p.m. ET, register here, or at the link below. Dr. Zoltan Szallasi will provide a high-level overview
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nWebinar to be hosted on Tuesday, March 21, 2023 at 12:00 p.m. ET, register here, or at the link below.\n\n\nDr. Zoltan Szallasi will provide a high-level overview of synthetic lethality, why synthetic lethality has become a desired trait for drugs in oncology, and an in-depth look at how Lantern is leveraging the synthetic lethality of its drug candidate LP-184 for several solid tumor types.\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on March 21, 2023 at 12:00 p.m. ET focusing on synthetic lethality, the unique and powerful mechanism of action behind Lantern’s drug candidates LP-184, LP-284, and LP-100.\n\nThe webinar will feature a leading expert on synthetic lethality in DNA damage repair (DDR) deficient tumors, Zoltan Szallasi, M.D., who serves joint appointments as group leader of the Translational Cancer Genomics Department at the Danish Cancer Society Research Center and as faculty of the Computational Health Informatics Program (CHIP) and Assistant Professor of Pediatrics at Boston Children's Hospital, which are affiliated with Harvard Medical School.\n\nDuring the webinar, Dr. Szallasi will discuss a broad range of topics surrounding synthetic lethality, including: a brief history of synthetic lethality in oncology, how synthetic lethality is being leveraged to successfully treat cancers with DDR deficiencies, the promising potential of LP-184’s synthetic lethality for DDR deficient tumors, and the potential to combine LP-184 with FDA approved agents to enhance LP-184’s anti-tumor potency. Details on the webinar and how to register can be found below:\n\nVirtual KOL Webinar Details:\n\n\nWhen: Tuesday, March 21, 2023 at 12:00 p.m. ET\n\n\nWebinar Length: 35 minutes\n\n\nRegistration Link:\nhttps://us06web.zoom.us/webinar/register/WN_SRl6B_BrRi6SUX8XzJnTrQ\n\n\nA replay of the webinar will be available on Lantern’s website beginning on March 21, 2023.\n\n\nAbout the Synthetic Lethality Mechanism of Action and LP-184:\n\nIn oncology drug development, synthetic lethality has become a highly desired cap...